The Investigation of Anti-Proliferative Effects of [Ag2(sac)2(dap)2] Complex on Different Types of Cancer
Abstract
Objective: Cytotoxic features of silver and saccharine compounds have taken attention due to the fact that most of them have showed a cytotoxic effect against tumor cells. In this study, it is aimed to investigate anti-proliferative effects of [Ag2(sac)2(dap)2] complex on different types of cancer cell lines.
Methods: HeLa (cervical cancer), PC-3 (prostate cancer), DU-145 (prostate cancer), A549 (non-small cell lung cancer), K562 (chronic myeloid leukemia) and MRC-5 (normal lung fibroblast) cell lines were grown in plates. In order to determine anti-proliferative effects, IC 50 values of [Ag2(sac)2(dap)2] and cisplatin on these cell lines were determined by MTT method.
Results: IC 50 value of [Ag2(sac)2(dap)2] complex was 19.53 ± 1.74 μM for HeLa cell line, 17.14 ± 1.41 μM for PC-3 cell line, 18.56 ± 4.04 for DU 145 cell line, 17.93 ± 1.06 μM for A549 cell line, 3.18 ± 0.04 μM for K562 cell line and 7.25 ± 1.00 μM for MRC-5 cell line. Also, IC 50 value of cisplatin was 4.00 ± 0.47 μM for HeLa cell line, 12.29 ± 1.60 μM for PC-3 cell line, 5.05 ± 0.65 for DU 145 cell line, 12.74 ± 1.26 μM for A549 cell line, 5.90 ± 0.59 μM for K562 cell line and 5.91 ± 0.32 μM for MRC-5 cell line. Only in K562 cell line, IC 50 of [Ag2(sac)2(dap)2] complex was lower than IC 50 of cisplatin.
Conclusion: Anti-proliferative activity of [Ag2(sac)2(dap)2] complex is more than cisplatin on chronic myeloid leukemia cells so this complex may be possible to be used as a treatment option especially for chronic myeloid leukemia.
Keywords
[Ag2(sac)2(dap)2,inorganic complex,cancer cell lines,anti-proliferation
References
- Ali KA, Abd-Elzaher MM and Mahmoud K. Synthesis and anticancer properties of silver (I) complexes containing 2, 6-Bis (substituted) pyridine derivatives. Int J Med Chem 2013; 256836.
- Ari F, Aztopal N, Icsel C, Yilmaz VT, Guney E, Buyukgungor O, Ulukaya E. Synthesis, structural characterization and cell death-inducing effect of novel palladium (II) and platinum (II) saccharinate complexes with 2-(hydroxymethyl) pyridine and 2-(2-hydroxyethyl) pyridine on cancer cells in vitro. Bioorgan Med Chem 2013;21(21): 6427-6434.
- Baran EJ, Yilmaz VT. Metal complexes of saccharin. Coordin Chem Rev 2006; 250(15-16): 1980-1999.
- Benedetti BT, Peterson EJ, Kabolizadeh P, Martínez A, Kipping R, Farrell NP. Effects of noncovalent platinum drug–protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism. Mol Pharmaceut 2011; 8(3): 940-948.
- Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011; 3(1): 1351-1371.
- Henderson W, Nicholson BK, McCaffrey LJ. Platinum (II) and palladium (II) saccharinate complexes. Inorg Chim Acta 1999; 285(1): 145-148.
- Kalinowska-Lis U, Felczak A, Checinska L, Szabłowska-Gadomska I, Patyna E, Malecki M, et al. Antibacterial activity and cytotoxicity of silver (I) complexes of pyridine and (Benz) imidazole derivatives. X-ray crystal structure of [Ag (2, 6-di (CH2OH) py) 2] NO3. Molecules 2016; 21(2): 87.
- Mourino V, Cattalini JP, Boccaccini AR. Metallic ions as therapeutic agents in tissue engineering scaffolds: an overview of their biological applications and strategies for new developments. J R Soc Interface 2012; 9(68): 401-419.
- Ndagi U, Mhlongo N, Soliman ME. Metal complexes in cancer therapy–an update from drug design perspective. Drug Des Dev Ther 2017; 11: 599.
- Siciliano TJ, Deblock MC, Hindi KM, Durmus S, Panzner MJ, Tessier CA, Youngs WJ. Synthesis and anticancer properties of gold (I) and silver (I) N-heterocyclic carbene complexes. J Organomet Chem 2011; 696(5): 1066-1071.